Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler, Walter P. Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Robin Besuyen, Thijs Hendrikx, Neelufar Mozaffarian, Ke Liu, Joy M. Greer, Atul Deodhar, Robert Landewé

Research output: Contribution to journalArticlepeer-review

120 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences